Recent advances in high-throughput proteomics have greatly enhanced biomarker discovery by improving the ability to identify and characterize biomarkers, creating new opportunities for understanding.
The success of biomarker discovery efforts depends not only on technological capabilities but also on rigorous cohort design, standardized sample handling, high-quality data generation and scalable informatics solutions.
This webinar will present an integrated approach that combines minimally invasive plasma proteomics with tissue-based proteogenomic analysis to explore the molecular foundations of disease. Specifically, the speaker will discuss the profiling of 500 plasma samples using two complementary high-throughput platforms — mass spectrometry and Olink — and the analysis of matched formalin-fixed paraffin-embedded (FFPE) tissue from a subset of participants through integrated proteomic and genomic workflows.
Key discussion points will include how genomics can inform proteomics, how proteomics reveals downstream protein-level effects, the advantages of integrated proteogenomic strategies in uncovering novel biological insights and the value of employing mass spectrometry and Olink proteomic platforms to achieve a more comprehensive biomarker landscape.
Register for this webinar to learn how multi-omics integration enhances disease characterization and supports biomarker discovery and the development of robust, clinically relevant biomarkers.
- Basic Research ,
- Bioanalytical Testing ,
- Biomarker Analysis ,
- Biomarker Discovery ,
- Biomarkers ,
- Blood Biomarkers ,
- Clinical Research ,
- Drug Development ,
- Genomic Analysis ,
- Genomic Data ,
- Genomics ,
- Genomics Research ,
- Mass Spectrometry ,
- Other Research ,
- Protein Biomarker ,
- Proteomic Analysis ,
- Proteomics ,
- Translational Research
Speaker
Jessica Moore, PhD, Senior Scientist II Proteomics, Discovery Life Sciences
With a strong foundation in mass spectrometry, Dr. Moore specializes in the integration of high-plex proteomics data, such as from Olink platforms, with liquid chromatography-tandem mass spectrometry (LC-MS/MS) datasets to advance multi-omics research.
In her current role, Dr. Moore focuses on innovative sample preparation methodologies and non-invasive biomarker discovery, collaborating with interdisciplinary teams to apply cutting-edge technologies in the study of biological systems. Her work has contributed to a deeper understanding of disease progression, molecular mechanisms of action, and the translation of omics data into actionable insights for human health and industrial applications. Dr. Moore’s commitment to fostering collaborative research with customers and fellow Discovery colleagues has positioned her as a key contributor in the evolving field of proteogenomics, bridging proteomics with genomic and transcriptomic analyses to drive precision medicine forward.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Biomarker Discovery Scientists: Researchers focused on identifying and validating biomarkers for disease diagnosis, prognosis or therapeutic response
- Proteomics and Genomics Researchers: Scientists specializing in high-throughput proteomics (e.g., mass spectrometry, Olink) or genomic analyses to study biological systems
- Translational Research Scientists: Professionals bridging preclinical and clinical research to translate omics data into clinical applications
- Bioinformatics and Data Scientists: Experts analyzing multi-omics datasets to uncover biological insights and support biomarker development
- Clinical Research Directors: Leaders overseeing cohort studies or clinical trials requiring robust biomarker profiling from biofluids or tissues
- Pharmaceutical R&D Managers: Decision-makers in drug development seeking scalable, integrative omics approaches to inform target identification and validation
What You Will Learn
Attendees will learn:
- How genomics can drive and inform proteomics analysis
- How proteomics can support genomic insights by expanding knowledge into the expressed/functional proteome
- The value of integrating proteomics and genomics workflows to reveal biology and biomarkers in combination
- The advantages of using complementary proteomics approaches — Olink and MS technologies — to drive biological understanding
Xtalks Partner
Discovery Life Sciences
Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of therapeutics and diagnostics that improve patient outcomes. Their extensive portfolio of biospecimens, cellular starting materials, and preclinical ADME-tox solutions accelerates research with reliable, high-quality products and expertise. Through a comprehensive suite of specialty lab services in genomics, proteomics, cell biology, and molecular pathology, Discovery delivers critical data and insights for biomarker discovery and both retrospective and prospective clinical trials. With a vision to be the most trusted partner in life science research and clinical development, Discovery Life Sciences is committed to advancing life sciences and transforming lives. Visit www.dls.com for more information.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account